Traf6: A Protein in The TNF Receptor Signaling Pathway (G7189)

Target Name: TRAF6

NCBI ID: G7189

TRAF6

Traf6: A Protein in The TNF Receptor Signaling Pathway

Traf6, also known as TNF receptor associated factor 6, is a protein that plays a crucial role in various cellular processes. It is a member of the TNF receptor signaling pathway, which is involved in a wide range of physiological processes including inflammation, cell signaling, and stress response. Traf6 has been identified as a potential drug target and has been the subject of intense research in recent years.

Traf6 is a 21-kDa protein that is expressed in various tissues, including muscle, bone, liver, and brain. It is highly conserved and has a similar structure to other proteins in the TNF receptor signaling pathway, including MyD88. Traf6 is involved in the regulation of various cellular processes, including inflammation, cell signaling, and stress response.

One of the key functions of Traf6 is its role in the regulation of TNF signaling. TNF is a cytokine that plays a crucial role in the regulation of immune and inflammatory responses. Traf6 is involved in the regulation of TNF signaling by interacting with the TNF receptor. This interaction allows Traf6 to regulate the activity of the TNF receptor and to influence the behavior of cells in response to TNF signaling.

In addition to its role in TNF signaling, Traf6 is also involved in the regulation of other signaling pathways. It is a member of the PI3K/AKT signaling pathway, which is involved in the regulation of cell signaling and survival. Traf6 is also involved in the regulation of the NF-kappa-B signaling pathway, which is involved in inflammation and cellular stress response.

Traf6 has been shown to play a role in a wide range of diseases and conditions. For example, Traf6 has been shown to be involved in the development of cancer, including breast cancer and colon cancer. It is also involved in the regulation of inflammation, including the development of autoimmune diseases such as rheumatoid arthritis and lupus. Traf6 has also been shown to be involved in the regulation of cellular stress response, including the development of neurodegenerative diseases.

In addition to its role in disease, Traf6 is also a potential drug target. Researchers have identified several potential drugs that can inhibit the activity of Traf6, including PD-L1 inhibitors and inhibitors of the PI3K/AKT signaling pathway. These drugs have been shown to have potential therapeutic benefits in a wide range of diseases, including cancer, autoimmune diseases, and neurodegenerative diseases.

Traf6 is also a potential biomarker for a variety of diseases. For example, Traf6 has been shown to be involved in the regulation of cellular stress response, including the development of neurodegenerative diseases. It is also involved in the regulation of inflammation, including the development of autoimmune diseases. These factors make Traf6 a potential biomarker for a wide range of diseases, including cancer, autoimmune diseases, and neurodegenerative diseases.

In conclusion, Traf6 is a protein that plays a crucial role in various cellular processes. It is a member of the TNF receptor signaling pathway and is involved in the regulation of TNF signaling, as well as other signaling pathways. Traf6 has been shown to play a role in the development of a wide range of diseases and conditions, including cancer, autoimmune diseases, and neurodegenerative diseases. It is also a potential drug target and potential biomarker for these diseases. Further research is needed to fully understand the role of Traf6 in these processes and to develop effective treatments.

Protein Name: TNF Receptor Associated Factor 6

Functions: E3 ubiquitin ligase that, together with UBE2N and UBE2V1, mediates the synthesis of 'Lys-63'-linked-polyubiquitin chains conjugated to proteins, such as IKBKG, IRAK1, AKT1 and AKT2 (PubMed:11057907, PubMed:18347055, PubMed:19713527, PubMed:19465916). Also mediates ubiquitination of free/unanchored polyubiquitin chain that leads to MAP3K7 activation (PubMed:19675569). Leads to the activation of NF-kappa-B and JUN (PubMed:16378096, PubMed:17135271, PubMed:17703191). Seems to also play a role in dendritic cells (DCs) maturation and/or activation (By similarity). Represses c-Myb-mediated transactivation, in B-lymphocytes (PubMed:18093978, PubMed:18758450). Adapter protein that seems to play a role in signal transduction initiated via TNF receptor, IL-1 receptor and IL-17 receptor (PubMed:8837778, PubMed:19825828, PubMed:12140561). Regulates osteoclast differentiation by mediating the activation of adapter protein complex 1 (AP-1) and NF-kappa-B, in response to RANK-L stimulation (By similarity). Together with MAP3K8, mediates CD40 signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production (By similarity). Participates also in the TCR signaling by ubiquitinating LAT (PubMed:25907557, PubMed:23514740)

The "TRAF6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAF6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets